Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023
<!-- Name:DistributionId Value:8810464 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4577 -->…
Browsing Tag
AB729
Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD – The Liver…
HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729 and NA therapy Preclinical data suggest that AB-101, an oral PD-L1 inhibitor, in combination with an RNAi, may provide…
Arbutus Announces Three Poster Presentations with Clinical Data from AB-729 and Preclinical Data…
Conference Call and Webcast to discuss the new data being presented at AASLD scheduled for 8:45 AM ET, Friday, November 4, 2022 WARMINSTER, Pa., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a…
Arbutus Announces New Data on AB-729 in Late Breaker Poster Presentation at AASLD – The Liver…
Arbutus’ Lead Compound AB-729 Continues to be Safe and Effective at Reducing HBsAg in Patients with Chronic Hepatitis B HBsAg remains suppressed up to 28 weeks after discontinuation of AB-729 Repeat dosing of both 60 mg and 90 mg of…
Arbutus Announces New Data on AB-729 and AB-836 Programs with Presentation of Five Abstracts at the…
AB-729, dosed at 60 mg every 8 weeks, achieved a mean HBsAg decline of -1.87 log10 IU/mL at week 44, comparable to 60 mg dosed every 4 weeks AB-729 resulted in HBsAg declines below 100 IU/ml in 75% of treated subjects, and increased…